serotonin-dopamine activity modulators (SDAM)
- Treatment of schizophrenia.
- Adjunctive treatment of major depressive disorder.
Psychotropic activity may be due to partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at the 5-HT2A receptor.
- Decreased manifestations of schizophrenia including excitable, paranoic, or withdrawn behavior.
- Improvement in symptoms of depression with increased sense of wellbeing.
Absorption: Well absorbed (95%) following oral administration.
Distribution: Displays extravascular distribution.
Protein Binding: >99%.
Metabolism and Excretion: Metabolized by CYP3A4 and CYP2D6; 25% excreted in urine (<1% unchanged), 46% in feces (14% unchanged).
Half-life: 91 hr.
TIME/ACTION PROFILE (improvement in symptoms)
|PO (schizophrenia)||within 1–2 wk||4–6 wk||unknown|
|PO (depression)||within 1 wk||5 wk||unknown|
Use Cautiously in:
- History of seizures, concurrent use of medications that may ↓ seizure threshold;
- Pre-existing cardiovascular disease, dehydration, hypotension, concurrent antihypertensives, diuretics, electrolyte imbalance (↑ risk of orthostatic hypotension, correct deficits before treatment);
- Pre-existing low WBC (may ↑ risk of leukopenia/neutropenia;
- History of diabetes, metabolic syndrome or dyslipidemia (may exacerbate);
- Patients <24 yr (may ↑ suicidal ideation/behaviors, monitor carefully);
- Patients at risk for falls;
- Poor CYP2D6 metabolizers (PM), dose ↓ required;
- Geri: Elderly patients with dementia-induced psychoses (↑ risk of serious adverse cardiovascular reactions and death), consider age, concurrent medical conditions and medications, renal/hepatic/cardiac function;
- OB: Safety not established; use during third trimester may result in extrapyramidal/withdrawal symptoms in infant;
- Lactation: Consider health benefits against risk of adverse effects in infant;
- Pedi: Safety and effectiveness not established (may ↑ suicidal ideation/behaviors).
Adverse Reactions/Side Effects
CNS: SEIZURES, abnormal dreams, dizziness, drowsiness, headache, restlessness., urges (eating, gambling, sexual, shopping)
EENT: blurred vision
CV: cerebrovascular adverse reactions (↑ in elderly patients with dementia-related psychoses), orthostatic hypotension/syncope
GI: abdominal pain, constipation, diarrhea, dry mouth, dysphagia, excess salivation, flatulence
Hemat: agranulocytosis, leukopenia, neutropenia
Metabolic: ↑ appetite, ↑ weight, hyperglycemia/diabetes, dyslipidemia
Neuro: akathisia, dystonia, extrapyramidal symptoms, tardive dyskinesia, tremor
Misc: NEUROLEPTIC MALIGNANT SYNDROME, ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS, body temperature dysregulation
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
- Concurrent use with strong CYP3A4 inhibitors including clarithromycin, itraconazole or ketoconazole ↑ blood levels, effects and risk of adverse reactions; ↓ dose of brexpiprazole required.
- Concurrent use with strong CYP2D6 inhibitors including fluoxetine, paroxetine, or quinidine↑ blood levels, effects and risk of adverse reactions; ↓ dose of brexpiprazole required.
- Combined use of strong or moderate CYP3A4 inhibitors with strong or moderate CYP2D6 inhibitors in addition to brexpiprazole including the following combinations itraconazole + quinidine, fluconazole + paroxetine, itraconazole + duloxetine or fluconazole + duloxetine ↑ blood levels, effects and risk of toxicity; ↓ dose of brexpiprazole required.
- Concurrent use of strong inducers of CYP3A4 including rifampin↓ blood levels and effectiveness; ↑ dose of brexpiprazole required.
- Concurrent use of antihypertensives or diuretics (↑ risk of hypotension).
- Concurrent use of medications that may ↓ seizure threshold (↑ risk of seizures).
Concurrent use of St. John's wort ↓ blood levels and effectiveness; ↑ dose of brexpiprazole required.
PO (Adults) Schizophrenia–1 mg once daily for the 1st 4 days (Days 1–4), then ↑ to 2 mg once daily for the next 3 days (Days 5–8), then ↑ to 4 mg once daily on Day 8 (not to exceed 4 mg once daily); Major depressive disorder–0.5 or 1 mg once daily initially, may be ↑ to 2 mg once daily (not to exceed 3 mg once daily); Known CYP2D6 poor metabolizers–use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors–use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors–use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors–use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers–double usual dose over 1–2 wk; titrate by clinical response.Hepatic Impairment
PO (Adults) Moderate to severe hepatic impairment [Child-Pugh score ≥7]–maximum daily dose should not exceed 3 mg for schizophrenia or 2 mg for major depressive disorder.
PO (Adults) Moderate/severe/end-stage renal impairment [CCr <60 mL/min]–maximum daily dose should not exceed 3 mg for schizophrenia or 2 mg for major depressive disorder.
Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg
- Assess mental status (orientation, mood, behavior) before and periodically during therapy. Assess for suicidal tendencies, especially during early therapy for depression. Restrict amount of drug available to patient. Risk may be increased in children, adolescents, and adults ≤24 yrs.
- Assess weight and BMI initially and throughout therapy.
- Obtain fasting blood glucose and cholesterol levels initially and periodically during therapy.
- Monitor BP (sitting, standing, lying), pulse, and respiratory rate before and periodically during therapy.
- Observe patient carefully when administering medication to ensure that medication is actually taken and not hoarded or cheeked.
- Monitor patient for onset of akathisia (restlessness or desire to keep moving) and extrapyramidal side effects (parkinsonian–difficulty speaking or swallowing, loss of balance control, pill rolling of hands, masklike face, shuffling gait, rigidity, tremors; and dystonic–muscle spasms, twisting motions, twitching, inability to move eyes, weakness of arms or legs) periodically throughout therapy. Report these symptoms.
- Monitor for tardive dyskinesia (uncontrolled rhythmic movement of mouth, face, and extremities; lip smacking or puckering; puffing of cheeks; uncontrolled chewing; rapid or worm-like movements of tongue). Notify health care professional immediately if these symptoms occur, as these side effects may be irreversible.
- Monitor for development of neuroleptic malignant syndrome (fever, muscle rigidity, altered mental status, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, pallor, tiredness, loss of bladder control). Notify health care professional immediately if these symptoms occur.
- Assess for falls risk. Drowsiness, orthostatic hypotension, and motor and sensory instability increase risk. Institute prevention if indicated.
Lab Test Considerations:
Monitor CBC frequently during initial mo of therapy in patients with pre-existing or history of low WBC. May cause leukopenia, neutropenia, or agranulocytosis. Discontinue therapy if severe neutropenia (ANC <1000 mm3 occurs).
- Monitor blood glucose and cholesterol levels initially and periodically during therapy.
- PO Administer once daily without regard to meals.
- Advise patient to take medication as directed and not to skip doses or double up on missed doses. Take missed doses as soon as remembered unless almost time for the next dose. Do not stop taking brexpiprazole without consulting health care professional. Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
- Inform patient of possibility of extrapyramidal symptoms and tardive dyskinesia. Instruct patient to report these symptoms immediately.
- Advise patient to make position changes slowly to minimize orthostatic hypotension. Protect from falls.
- Medication may cause drowsiness and lightheadedness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- Advise patient and family to notify health care professional if thoughts about suicide or dying, attempts to commit suicide; new or worse depression; new or worse anxiety; feeling very agitated or restless; panic attacks; trouble sleeping; new or worse irritability; acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood occur.
- Inform patient that brexipiprazole may cause weight gain. Advise patient to monitor weight periodically. Notify health care professional of significant weight gain.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any new medications. Caution patient to avoid taking alcohol or other CNS depressants concurrently with this medication.
- Advise patient that extremes in temperature should be avoided, because this drug impairs body temperature regulation.
- Advise patient to notify health care professional if new or increased eating/binge eating, gambling, sexual, shopping, or other impulse control disorders occur.
- Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
- Advise female patients to notify health care professional if pregnancy is planned or suspected and to avoid breast feeding during therapy. Encourage pregnant patients to enroll in registry by contacting National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregi....
- Emphasize the importance of routine follow-up exams and continued participation in psychotherapy as indicated.
- Decrease in excitable, paranoic, or withdrawn behavior.
- Increased sense of wellbeing in patients with depression.
Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Complete Product Information.